A Half-Century of Neurotransmitter Research

A Career Built on Accidents and Ignored Advice

Arvid Carlsson's path to the Nobel Prize began with a professional slight. He had spent the early 1950s doing careful work on calcium metabolism — solid, internationally recognised science — until an expert committee evaluating him for a professorship told him, bluntly, that calcium metabolism was not central enough to pharmacology. So he changed fields.

He wrote to a colleague, who forwarded a letter to a chemist in Maryland, who forwarded it to his boss: Bernard Brodie, head of the Laboratory of Chemical Pharmacology at the US National Heart Institute, a man Carlsson describes in the lecture as a "sensation seeker" and self-described gambler who had started his career as a boxer before becoming one of the most celebrated figures in American biochemical pharmacology. Carlsson arrived at Brodie's lab in August 1955. The timing, as he puts it, was "extremely fortunate."

Brodie's lab had just discovered that reserpine — a drug used at the time as both a tranquiliser and a blood-pressure medication — caused the near-total disappearance of serotonin from brain tissue. Nobody yet knew what this meant. Carlsson proposed they look at catecholamines — a related family of molecules — for the same effect. Brodie waved him off: serotonin was the thing to focus on. But Carlsson, as he would do throughout his career, did it anyway.

The Molecule Nobody Cared About

At the time Carlsson began this work, dopamine was considered physiologically uninteresting — a mere chemical way-station on the route from the amino acid DOPA to noradrenaline, another signalling molecule. It had low activity on smooth-muscle preparations, which was how researchers tested these things. Nobody thought it did much on its own.

Carlsson and his colleague Nils-Åke Hillarp — a histologist whose brilliance he describes with the same admiration he reserved for Brodie — showed that reserpine depleted not just serotonin but catecholamines too, including dopamine. Reserpine-treated animals became profoundly sedated, barely able to move. When Carlsson then gave these animals L-DOPA — a precursor molecule that, unlike dopamine itself, can cross from the bloodstream into the brain — they recovered dramatically. The sedation reversed. The animals moved again.

This was the proof. Remove dopamine from the brain and the animal loses movement. Restore it and movement returns. The brain was, at least in part, talking to itself in chemistry. And dopamine was one of its crucial words — concentrated, they soon found, in the basal ganglia, a set of structures deep in the brain known to be involved in the control of movement. The connection to Parkinson's disease — a disorder of movement — was not far behind.

A Battle in London, and What It Took to Win It

In 1958 Carlsson presented his dopamine findings at the First International Catecholamine Symposium. A year and a half later, in March 1960, came the real confrontation: a Ciba Foundation Symposium in London, attended by nearly every eminent expert in the field. At its centre was Sir Henry Dale — Nobel laureate, eighty-five years old and still formidable — whose former students treated him, Carlsson writes, "like school children their headmaster."

Dale and the assembled experts had spent decades establishing the theory of chemical neurotransmission in the peripheral nervous system — the nerves outside the brain and spinal cord. But they remained fiercely sceptical that the brain itself communicated chemically. The dominant view still held that brain signals were electrical, jumping directly from neuron to neuron. The "sparks" versus "soup" debates, as they were known — electricity versus chemistry — had been going on for decades. The soup camp had made some inroads in the periphery, but the brain was seen as different.

Carlsson presented his data. The response was withering. The data were not disputed — some confirmatory animal experiments were even reported at the meeting — but the interpretation was rejected. Dale called L-DOPA a poison. Another prominent scientist concluded that the idea of dopamine functioning as a brain transmitter would not have a long life. In the concluding remarks, someone observed that nobody at the meeting had ventured to speculate about the relationship between catecholamines and brain function — even though this was precisely what Carlsson had been insisting on throughout. The implication was clear: he was nobody.

From Rabbits to Patients: the L-DOPA Story

The link between dopamine and Parkinson's disease crystallised when researchers in Vienna — Oleh Hornykiewicz and Herbert Ehringer — examined post-mortem brains from Parkinson's patients in 1960 and found that dopamine was almost entirely absent from the basal ganglia. The connection that Carlsson had drawn between dopamine depletion and movement loss, demonstrated in animals, was confirmed in human disease. Parkinson's was, at its root, a dopamine deficiency.

The logical treatment followed directly: if the disease was caused by too little dopamine, restore it. And since dopamine itself could not cross the blood-brain barrier, give patients L-DOPA — the precursor that could. Early clinical trials in the 1960s were transformative. Patients who had been near-immobile began to move again. It was, by any measure, one of the most dramatic pharmaceutical successes of the twentieth century.

L-DOPA remains, more than sixty years later, the cornerstone treatment for Parkinson's disease. It does not cure the disease — the dopamine-producing neurons continue to die — but it restores the chemical that those neurons are failing to produce, and for many patients it restores years of functional life. The drug has been refined, combined with other agents to reduce side effects, and adapted in various formulations, but the insight behind it is unchanged: it came from a rabbit that couldn't move, and a molecule that most scientists thought was doing nothing.

The Same Molecule, Two More Diseases

The dopamine story did not stop with Parkinson's. The same research that established dopamine's role in movement also opened two other vast territories: schizophrenia and depression. Both stories run through Carlsson's lecture, and both are still playing out in pharmacies and clinics today.

On schizophrenia: Carlsson and Margit Lindqvist showed in 1963 that chlorpromazine and haloperidol — the first generation of antipsychotic drugs — increased the turnover of dopamine in the brain, suggesting they were blocking dopamine receptors. This led to the dopamine hypothesis of schizophrenia: that the disorder involves excess dopamine activity in certain brain circuits. The hypothesis was partially right — antipsychotic drugs do work partly by blocking dopamine, and the evidence for overactive dopamine signalling in psychosis is substantial — but Carlsson spent decades refining it. His later work pointed toward a more complex picture involving multiple neurotransmitter systems, including glutamate, and proposed that the core problem in schizophrenia might actually be too little dopamine in certain circuits, driving compensatory overactivity elsewhere.

On depression: Carlsson's lab at Gothenburg developed the first selective serotonin reuptake inhibitor — SSRI — a class of drug that would eventually become the most widely prescribed antidepressants in history. The compound was called zimelidine, synthesised in collaboration with pharmaceutical chemists at Astra/Hässle and launched in 1982. It worked well as an antidepressant, but was withdrawn the following year due to rare but serious neurological side effects. It was soon replaced by safer SSRIs — fluoxetine (Prozac), sertraline (Zoloft), and others — but the mechanism was Carlsson's. The entire SSRI revolution traces back to his laboratory's understanding of how serotonin is recycled at brain synapses, and what happens when you block that recycling.

What the Brain's Chemical Language Made Possible

Carlsson's lecture covers fifty years in twenty pages — a sweep from 1955 to 2000 that encompasses the discovery of chemical neurotransmission in the brain, the birth of modern psychopharmacology, the development of treatments for three of the most prevalent neurological and psychiatric disorders in the world, and a still-evolving theory of how the brain's chemical circuits go wrong and what we can do about it. Reading it is like watching a scientific field get built from the ground up, one experiment at a time, against sustained institutional scepticism.

The lecture also ends forward-looking. By 2000, Carlsson was working on what he called dopamine stabilisers — a new class of drugs designed not simply to block or boost dopamine, but to normalise its activity regardless of direction. The idea was elegant: a molecule that would dampen dopamine when it was overactive and stimulate it when it was underactive, acting as a chemical thermostat rather than a blunt switch. Preliminary clinical results at the time of the lecture suggested potential in Huntington's disease, Parkinson's-related movement complications, and schizophrenia. He was still running clinical trials in his late seventies, and this research continued after his death in 2018 at the age of ninety-five.

What makes this lecture worth sitting with is not just the science — it is the disposition behind it. Carlsson kept working on dopamine when experts told him it was unimportant. He kept arguing for chemical neurotransmission in London when the room's most decorated minds told him he was wrong. He kept refining the theory of schizophrenia for forty years after the first version was accepted, because he thought the first version was incomplete. The half-century of the title is not just a career span — it is a portrait of what patient, stubborn, unglamorous scientific work actually looks like.

Every patient who has taken L-DOPA for Parkinson's disease, or an SSRI for depression, or an antipsychotic for schizophrenia, is living inside the consequences of this work. That is not a small thing. It is the measure of what one curious pharmacologist, willing to ignore the advice of his expert committee and do it anyway, managed to find.